Johannes D Veldhuis1, Daniel M Keenan. 1. Endocrine Research Unit, Mayo Medical and Graduate Schools, Mayo Clinic, Rochester, Minnesota 55905, USA. veldhuis.johannes@mayo.edu
Abstract
BACKGROUND: GH pulses are putatively initiated by hypothalamic GH-releasing hormone (GHRH), amplified by GH-releasing peptide (GHRP), and inhibited by somatostatin (SS). OBJECTIVE: To ascertain how secretagogues control the waveform (time evolution of release rates) as well as the mass of secretory bursts. DESIGN: We quantified the shape of GH secretory bursts evoked by continuous combined i.v. infusion of maximally effective doses of GHRH and GHRP-2, and by bolus injection of each peptide after delivering L-arginine to restrain hypothalamic SS release in 12 healthy young men. METHODS: A mathematically verified and experimentally validated variable-waveform deconvolution model was applied to intensively sampled GH time series. RESULTS: The secretory-burst mode (time from burst onset to maximal secretion) was 19+/-0.69 min during saline infusion, and fell to a) 10.4+/-3.0 min during constant dual stimulation with GHRH/GHRP-2 (P<0.01), b) 14.6+/-1.8 min after l-arginine/GHRH (P<0.025), and c) 15.0+/-1.0 min after l-arginine/GHRH (P<0.01). Secretagogues augmented the mass of GH secreted in pulses by 44-, 42-, and 16-fold respectively, over saline (2.2+/-0.81 microg/l per h; P<0.001 for each). Pulse number and variability were unaffected. Applying the same methodology to ten other young men with acute leuprolide-induced hypogonadism yielded comparable waveform and mass estimates. CONCLUSION: The present analyses in men demonstrate that peptidyl secretagogues modulate not only the magnitude but also the time course of the GH-release process in vivo independently of the short-term sex-steroid milieu.
BACKGROUND:GH pulses are putatively initiated by hypothalamic GH-releasing hormone (GHRH), amplified by GH-releasing peptide (GHRP), and inhibited by somatostatin (SS). OBJECTIVE: To ascertain how secretagogues control the waveform (time evolution of release rates) as well as the mass of secretory bursts. DESIGN: We quantified the shape of GH secretory bursts evoked by continuous combined i.v. infusion of maximally effective doses of GHRH and GHRP-2, and by bolus injection of each peptide after delivering L-arginine to restrain hypothalamic SS release in 12 healthy young men. METHODS: A mathematically verified and experimentally validated variable-waveform deconvolution model was applied to intensively sampled GH time series. RESULTS: The secretory-burst mode (time from burst onset to maximal secretion) was 19+/-0.69 min during saline infusion, and fell to a) 10.4+/-3.0 min during constant dual stimulation with GHRH/GHRP-2 (P<0.01), b) 14.6+/-1.8 min after l-arginine/GHRH (P<0.025), and c) 15.0+/-1.0 min after l-arginine/GHRH (P<0.01). Secretagogues augmented the mass of GH secreted in pulses by 44-, 42-, and 16-fold respectively, over saline (2.2+/-0.81 microg/l per h; P<0.001 for each). Pulse number and variability were unaffected. Applying the same methodology to ten other young men with acute leuprolide-induced hypogonadism yielded comparable waveform and mass estimates. CONCLUSION: The present analyses in men demonstrate that peptidyl secretagogues modulate not only the magnitude but also the time course of the GH-release process in vivo independently of the short-term sex-steroid milieu.
Authors: Daniel M Keenan; Ferdinand Roelfsema; Nienke Biermasz; Johannes D Veldhuis Journal: Am J Physiol Regul Integr Comp Physiol Date: 2003-05-08 Impact factor: 3.619
Authors: M J Bray; T M Vick; N Shah; S M Anderson; L W Rice; A Iranmanesh; W S Evans; J D Veldhuis Journal: J Clin Endocrinol Metab Date: 2001-07 Impact factor: 5.958
Authors: Deepankar K Sinha; Adithya Balasubramanian; Alexander J Tatem; Jorge Rivera-Mirabal; Justin Yu; Jason Kovac; Alexander W Pastuszak; Larry I Lipshultz Journal: Transl Androl Urol Date: 2020-03